Mid-Year Biotech Deal Trends: Key Structures Driving 2026 Transactions

Biotech deal activity in the first half of 2026 reflects a market recalibrating after two years of tightened capital — and the structures reflect that caution. Option-to-acquire arrangements remain the dominant Big Pharma–biotech partnership structure, allowing acquirers to purchase rights to a program after Phase 2 readouts, limiting upfront exposure while preserving access to promising science.

Collaboration and license agreements continue to dominate earlier-stage deals, with milestone-heavy structures that shift value to the back end. Development, regulatory, and commercial milestones can collectively represent 10–20x the upfront payment — making the triggering conditions of each milestone among the most negotiated provisions in any life sciences deal.

Royalty stacking — the accumulation of royalty obligations across multiple in-licensed IP rights — remains a persistent risk that buyers frequently underestimate in diligence. Freedom-to-operate analysis and chain-of-title review continue to be the top areas where deals slow down or collapse. Companies with clean, documented IP ownership and current FTO opinions close faster and at better economics.